Test ID: Infliximab antibodies
|
Infliximab antibodies
|
Infliximab antibodies
|
Useful For
|
The assessment of non-response or loss of response to infliximab.
|
Method name and description
|
An enzyme-linked immunosorbent assay (ELISA) is used for the measurement of infliximab antibodies.
|
Clinical information
|
Inflammatory conditions such as ulcerative colitis, Crohn disease, and rheumatoid arthritis can be treated with a variety of immunomodulatory drugs such as infliximab. Some patients may not respond to infliximab treatment (primary non-responders) whilst others may initially respond but the efficacy diminishes over time (secondary non-responders). The assessment of infliximab antibodies may indicate the likely cause of non-response and inform whether infliximab treatment should be increased, or stopped in favour of a different drug.
|
Aliases
|
Anti-Infliximab antibodies
Anti-IFX Ab
Anti-Remicade antibodies
Anti-Remicade Ab
|
|
Specimen type / Specimen volume / Specimen container
|
Specimen type: Blood (serum)
Specimen Volume: 0.5 mL serum, separate the serum as quickly as possible to avoid hemolysis.
Specimen container: gel tube (yellow top) or red top tube
|
Collection instructions / Special Precautions / Timing of collection
|
Therapy phase must be specified on request.
|
Storage and transport instructions
|
Blood samples can be transported at ambiant temperature as quickly as possible.
Serum samples are stable for up to 3 - 4 days at 2-8°C.
Serum samples are stable for up to 1 year when frozen at -20°C. Frozen samples should be kept frozen during transport. Avoid freeze-thaw cycles.
|
Specimen Rejection Criteria
|
- Samples that are grossly haemolysed.
- Insufficient sample quantity.
|
|
Biological reference intervals and clinical decision values
|
Interpretation:
|
Positive
|
Negative
|
|
Turnaround time / Days and times test performed / Specimen retention time
|
- Turnaround time: 10 working days.
- Days and times test performed: once every two weeks.
- Specimen retention time: 4 days.
|
|
|